FDA approves atezolizumab plus chemotherapy for stage III dMMR colon cancer
A Cochrane review links drug-company promotion to less appropriate prescribing, the FDA approves atezolizumab for stage III dMMR colon cancer, and an early optogenetics trial restores some light sensitivity in retinitis pigmentosa.
Cochrane review ties drug-company gifts and marketing to worse prescribing
A Cochrane review ties drug-company gifts and marketing to worse prescribing, the Bundibugyo Ebola outbreak becomes the second-largest on record, and U.S. measles cases reach 4,080 for 2026.